<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157559</url>
  </required_header>
  <id_info>
    <org_study_id>2006-Zeldox in FEP</org_study_id>
    <nct_id>NCT01157559</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety With Ziprasidone in First-episode Psychosis</brief_title>
  <official_title>Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the efficacy and safety of ziprasidone in patients
      with first episode psychosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms assessment by objective rating scales</measure>
    <time_frame>week 1</time_frame>
    <description>PANSS total score, SANS, clinical global impression scale, GAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms assessment by objective rating scales</measure>
    <time_frame>week 2</time_frame>
    <description>PANSS total score, SANS, clinical global impression scale, GAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms assessment by objective rating scales</measure>
    <time_frame>week 4</time_frame>
    <description>PANSS total score, SANS, clinical global impression scale, GAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms assessment by objective rating scales</measure>
    <time_frame>week 6</time_frame>
    <description>PANSS total score, SANS, clinical global impression scale, GAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms assessment by objective rating scales</measure>
    <time_frame>week 8</time_frame>
    <description>PANSS total score, SANS, clinical global impression scale, GAF, DAS-S</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events by objective rating scales and self report scales</measure>
    <time_frame>one-month</time_frame>
    <description>Simpson and Angus rating scale, Barnes Akathisia rating scale and Abnormal Involuntary Movement Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events by objective rating scales and self report scales</measure>
    <time_frame>two-month.</time_frame>
    <description>Simpson and Angus rating scale, Barnes Akathisia rating scale and Abnormal Involuntary Movement Scale</description>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>First Episode Psychosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>8 week prospective study</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet DSM-IV criteria for first episode schizophrenia, schizophreniform
             disorder and schizoaffective disorder

        Exclusion Criteria:

          -  Patients with previously prescribed antipsychotic medication in 2 weeks or more

          -  patients with substance-induced psychotic disorder, serious suicide attempt,
             neurological disorder, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, Chonbuk national University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heo psychiatric Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeonju Jesus Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Young Chul Chung/Professor of Psychiatry</name_title>
    <organization>Chonbuk National University Hospital, Jeonju, Korea</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

